The drug is administered intravenously in a three-dose schedule over approximately one month. Image courtesy of Dendreon Corporation.
-
Provenge (sipuleucel-T) is an autologous cellular immunotherapy. -
Provenge works by stimulating the immune system by activating the T-cells of... -
In 2010, Provenge was approved by FDA for treating men with advanced prostate... -
The drug is administered intravenously in a three-dose schedule over roughly...
